According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Subscribe To Our Newsletter & Stay Updated
